JSJuan Carlos Solis-Poblano

Juan Carlos Solis-Poblano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Carlos Solis-Poblano has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Limited Access to Systemic Lupus Erythematosus: A Systematic Review

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Juan Carlos Solis-Poblano, Jorge Ayón-Aguilar, Socorro Méndez-Martínez, Gabriela Medina Valeriano, Máximo Alejandro García Flores

    Introduction:: Inequities in systemic lupus erythematosus (SLE) care affect outcomes (i.e., flares, damage, mortality), interventions (referrals, advanced therapies), and populations (gender, race/ethnicity, and geographic region). This systematic review highlights themes related to access to care for SLE patients and explores potential solutions to address these disparities. Methods:: In adherence to PRISMA guidelines, we conducted a systematic review of the literature. We searched for articles published in PubMed, Scopus, Web of Science, Cochrane Library, and EBSCO. Publications related to economic burden, barriers and facilitators to access, and potential solutions were included. Results:: A total of 77 articles were identified. Five critical issues concerning access to SLE care were revealed from the literature: (1) economic burden, (2) barriers and facilitators to access, (3) utilization, (4) adherence, and (5) possible solutions to improve healthcare access. Discussion:: The usual barriers and facilitators involved several social factors related to health (i.e., transportation, insurance, and limited access to mental health services, among others). Utilization of SLE care is influenced by socioeconomic status (SES), ethnicity, and education level. Factors like low education, low SES, rural residency, and depressive symptom adherence contribute to nonadherence. There were various proposals to improve access to SLE care, including peer support, digital platforms (e.g., telemedicine), and community-based programs (such as PALS and WELL). Conclusions:: The SLE care field highlights the inequalities that impact marginalized communities. Emphasizing community-based programs, addressing social determinants of health, acknowledging social exclusion, and adopting digital platforms can help reduce healthcare inequity.

  • Multiple myeloma in Mexico: a retrospective study on long-term survival in a publicly insured cohort

    by Juan Carlos Solis-Poblano, María Teresa Itzmoyotl-Hernández, Uendy Pérez-Lozano, Lilia Adela García-Stivalet, Jorge Luis López-Marthen, Rosa Silva-Ruacho, Patricia Zagoya-Martínez, Máximo Alejandro García-Flores, Claudia Mendoza-Pinto, Álvaro José Montiel-Jarquin, et al.

    We retrospectively analyzed 293 adults with multiple myeloma treated at a tertiary public center (2002-2024; 65% men; median age 58). Kaplan-Meier for survival estimation and Cox proportional-hazards models for associations. Median follow-up was 2.9 years; 47 (16%) underwent autologous stem-cell transplantation (ASCT). Overall survival (OS) at 3, 5, and 10 years were 84%, 76%, and 60%. ASCT was associated with higher unadjusted 10-year OS (74.1% vs 56.1%; p = 0.007), but was not significant after adjustment (p = 0.20). In multivariable analyses, higher hemoglobin was protective (HR 0.79; 95% CI 0.67-0.92; p = 0.003), and higher lactate dehydrogenase was associated with mortality (HR 1.63 per 100 U/L; 95% CI 1.13-2.36; p = 0.010). Progression-free survival (PFS) was assessed in all patients; 134 PFS events occurred, and the median PFS was 3.9 years. Findings support LDH-informed risk stratification and timely ASCT referral in resource-limited settings and suggest a pragmatic, FISH-free prognostic approach incorporating hemoglobin where cytogenetics are unavailable.


  • Open Access

    Artificial intelligence in patient education: evaluating large language models for understanding rheumatology literature

    by Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Juan Carlos Solis-Poblano, Máximo Alejandro García-Flores, Jorge Ayón-Aguilar

    Background: Inadequate health literacy hinders positive health outcomes, yet medical literature often exceeds the general population's comprehension level. While health authorities recommend patient materials be at a sixth-grade reading level, scientific articles typically require college-level proficiency. Large language models (LLMs) like ChatGPT show potential for simplifying complex text, possibly bridging this gap.Objective: This study evaluated the effectiveness of ChatGPT 4.0 in enhancing the readability of peer-reviewed rheumatology articles for layperson comprehension.Methods: Twelve open-access rheumatology articles authored by the senior investigators were included. Baseline readability was evaluated utilizing Flesch-Kincaid Grade Level (FKGL) and Simple Measure of Gobbledygook (SMOG) indices. Each article was processed by ChatGPT 4.0 with a prompt requesting simplification to a sixth-grade level. Two expert rheumatologists evaluated the generated summaries’ appropriateness (accuracy, absence of errors/omissions). Readability changes were analyzed using paired t-tests.Results: ChatGPT significantly improved readability (P < .0001), reducing the average reading level from approximately 15th grade (FKGL: 15.06, SMOG: 14.08) to 10th grade (FKGL: 10.52, SMOG: 9.48). The expert reviewers deemed the generated summaries appropriate and accurate. The average word count was significantly reduced from 3,517 to 446 words (P = 0.047).Conclusions: ChatGPT effectively lowered the reading complexity of specialized rheumatology literature, making it more accessible than the original publications. However, the achieved 10th-grade reading level still exceeds the recommended sixth-grade level for patient education materials. While LLMs are a promising tool, their output may require further refinement or expert review to meet optimal health literacy standards and ensure equitable patient understanding in rheumatology.


  • Evaluation of Patient Information Provided by ChatGPT on Antimalarial Use in Systemic Lupus Erythematosus: Spanish Language Translation

    by Pamela Munguía‐Realpozo, Claudia Mendoza‐Pinto, Ivet Etchegaray‐Morales, Socorro Méndez‐Martínez, Edith Ramírez‐Lara, Juan Carlos Solis‐Poblano, Máximo Alejandro García Flores


  • Open Access

    Correction to: Trends in mortality in patients with systemic autoimmune rheumatic diseases (SARD) during the COVID-19 pandemic in Mexico

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Juan Carlos Solis-Poblano, Jorge Ayón-Aguilar, Edith Ramírez-Lara, Jacsiry Orbe-Sosa, Socorro Méndez-Martínez, Mario García-Carrasco

  • Trends in the disease burden of musculoskeletal disorders in Mexico from 1990–2019

    by Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Pamela Munguía-Realpozo, Juan Carlos Solis-Poblano, Ángel David Osorio-Peña, Diana Zárate-Arellano, Socorro Méndez-Martínez, Mario García-Carrasco

    Objective This study aimed to describe the disease burden and trends of musculoskeletal (MSK) disorders in Mexico from 1990 to 2019. Method A cross-sectional study using systematic analysis from the Global Burden of Disease Study 2019 (GBD study 2019) was performed to analyze data on MSK disorders and estimate crude and age-standardized rates per 100,000 population concerning disease prevalence, incidence, mortality, disability-adjusted life-years (DALY), and years lived with disability (YLD). The average annual percentage change (AAPC) was calculated using the joinpoint regression. Results In 2019, there were 4.8 million (95% UI 4.3, 5.4) new cases and 3,312 (95% UI 2201, 4,790) deaths attributable to MSK disorders. In 2019, MSK disorders ranked first, increasing from 1990 (second rank) for the YLD in Mexico. Subnational variations were identified, with the state of Oaxaca having the highest age-standardized incidence rate (ASIR) per 100,000 population in 2019. Joinpoint analysis revealed a significant increase in prevalence in Mexico from 1990 to 2019 (AAPC: 0.14%; 95%CI 0.09–0.19), incidence (AAPC: 0.05%; 95%CI 0.03–0.07), DALY (AAPC: 0.13%; 95%CI 0.04–0.22), and YLD (AAPC: 0.13%; 95%CI 0.02–0.24). Among the risk factors, occupational ergonomic factors and high body mass index (BMI) had the largest influence on MSK disorders. Conclusions In Mexico, we observed an increase the national burden of MSK disorders from 1990 to 2019. Specific determinants, such as occupational ergonomic factors and high BMI, contribute to the MSK disorder burden. The burden of MSK disorders requires an improved and prompt assessment to plan valuable diagnostic and management approaches. Key Points • In Mexico, the burden of musculoskeletal (MSK) disorders increased from 1990 to 2019. • Specific risk factors, such as occupational ergonomic factors and high body mass index, contribute to the MSK disorder burden.


  • Open Access

    Trends in mortality in patients with systemic autoimmune rheumatic diseases (SARD) during the COVID-19 pandemic in Mexico

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Juan Carlos Solis-Poblano, Jorge Ayón-Aguilar, Edith Ramírez-Lara, Jacsiry Orbe-Sosa, Socorro Méndez-Martínez, Mario García-Carrasco

    The study aimed to analyze the influence of the COVID-19 pandemic on mortality rates in patients with systemic autoimmune rheumatic diseases (SARD) in Mexico. We selected SARD-related deaths using National Open Data and Information from the Ministry of Health, Mexico, and ICD-10 codes. We assessed the observed compared to the predicted mortality values for 2020 and 2021, employing trends from 2010 to 2019 with joinpoint and prediction modelling analyses. Among 12,742 deaths due to SARD between 2010 and 2021, the age-standardized mortality rate (ASMR) increased significantly between 2010 and 2019 (pre-pandemic) (annual percentage change [APC] 1.1%; 95% CI 0.2–2.1), followed by a non-significant decrease during the pandemic period (APC 13.9%; 95% CI 13.9–5.3). In addition, the observed ASMR of 1.19 for 2020 for SARD and of 1.14 for 2021 were lower than the predicted values of 1.25 (95% CI 1.22–1.28) for 2020 and 1.25 (95% CI 1.20–1.30) for 2021. Similar findings were identified for specific SARD, mainly systemic lupus erythematosus (SLE), or by sex or age group. Interestingly, the observed mortality rates for SLE in the Southern region of 1.00 in 2020 and 1.01 in 2021 were both significantly greater than the predicted values of 0.71 (95% CI 0.65–0.77) in 2020 and 0.71 (95% CI 0.63–0.79). In Mexico, the observed SARD mortality rates were not higher than the expected values during the pandemic, except for SLE in the Southern region. No differences by sex or age group were identified.